Virtual Library
Start Your Search
T. Nakamura
Author of
-
+
P3.07 - Poster Session/ Small Cell Lung Cancer (ID 223)
- Event: WCLC 2015
- Type: Poster
- Track: Small Cell Lung Cancer
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.07-013 - A Retrospective Analysis of Adjuvant Chemotherapy in Patients with Completely Resected SCLC (ID 1418)
09:30 - 09:30 | Author(s): T. Nakamura
- Abstract
Background:
Several clinical studies have demonstrated the efficacy and safety of the adjuvant chemotherapy for patients with small cell lung cancer (SCLC) , particularly in patients with stage Ⅰ disease. But it is unclear which chemotherapy regimen is the most efficacious for SCLC patients who underwent surgery, due to the rarity. The objective of this study was to analyze the efficacy and safety of adjuvant chemotherapy for patients with SCLC retrospectively.
Methods:
From January 2002 to September 2014, we retrospectively analyzed the clinical data of 23 patients with SCLC who received surgery in our institute. Seventeen patients received adjuvant chemotherapy. Six patients was observed with no chemotherapy after surgery, due to old age or poor condition（n=4）, patient refusal（n=1）, early post-operative relapse（n=1）.
Results:
The chemotherapy regimens were cisplatin and etoposide（PE）in 8 patients, and carboplatin and etoposide （CE） in 9 patients. Median time from surgery to starting chemothetapy was 1.5 months, and median follow-up time was 39.5 months. 12 pts （70%） received full cycles of chemotherapy. The recurrence was observed in 2 of 8 pts who received PE therapy and 2 of 9 patients who received CE therapy in April 2015. The median recurrence free survival (RFS) of patients who received adjuvant chemotherapy was not reached, and the RFS of patients with no chemotherapy was 7.62 months（Log-rank test P value 0.0007）. No treatment related death was observed.
Conclusion:
The adjuvant chemotherapy for patients with small cell lung cancer may be safe and efficatious.
